Logo

Ciphergen, BioMerieux Partner for Biomarker Discovery

Jun 30, 2003

NEW YORK, June 30 - Ciphergen Biosystems and diagnostics firm BioMerieux have entered a collaboration using Ciphergen's ProteinChip technology to discover biomarkers that may improve the diagnosis and management of colon cancer, Ciphergen said today.

 

Ciphergen will install its technology platform at BioMerieux's Marcy-l'Etoile, France, site and the company's Biomarker Discovery Center team will collaborate with BioMerieux's research team.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.